Two economic analyses demonstrated the DERMABOND® PRINEO® Skin Closure system, made by Ethicon, is associated with improved patient outcomes and lower healthcare costs for hospitals, the company said.
Both studies were presented at the International Society for Pharmacoeconomics and Outcomes Research conference in Boston last week.
The first study found the system was associated with improved outcomes for patients receiving total knee arthroplasty when compared to skin staples. The findings are based on a retrospective analysis of 1,942 TKA procedures. It was associated with a significant reduction in readmission rates at 30, 60 and 90 days, a reduction in length of hospital stay and a lower probability of being discharged to a skilled nursing facility, the analysts found.
The 30-day readmission rate for the DERMABOND PRINEO System group was 1.8%, compared to 4.4% for the skin staple group. In the second study, analysts looked at cost savings, and found an estimated $28,349, compared to $10,000 more, when assuming 500 arthroplasties.
The predicted cost savings were driven by reductions in dressing materials and postoperative healthcare visits, the researchers said.
“Ethicon is committed to bringing to market innovative products that are designed to provide improved outcomes for patients and enable our customers to provide the best care for their patients,” says Nefertiti Greene, Vice President, Global Wound Closure and Repair Platform Leader at Ethicon. “The DERMABOND PRINEO System has been shown by this research to be an excellent approach to wound closure.”
Some of the benefits, such as a lower hospitalization rate, could relate to the product providing significantly greater skin holding strength than skin staples and subcuticular suture, the company said. The system also acts as a barrier to microbial penetration against organisms commonly associated with surgical site infections.
